Glenmark Pharmaceuticals Ltd.
Research Glenmark Pharmaceuticals Ltd. (GLENMARK.NS) on Bullrun: market cap INR 628.43B, P/E 35.0, dividend yield 0.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGLENMARK.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 628.43B
- P/E35.0
- Dividend yield0.1%
- Financial periodQ2 2026
- RevenueINR 39.32B
- Net incomeINR 4.83B
- Gross margin68.3%
Valuation Snapshot
latest market cap is INR 628.43B; P/E is 35.0; dividend yield is 0.1%.
Peer valuation comparison
Latest P/E is 34.96x versus a Healthcare sector median of 21.74x (60.8% above).
Latest dividend yield is 0.11% versus a Healthcare sector median of 2.4% (95.4% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 628.43B | 35.0 | 0.1% | 2.5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 2.5 INR, yield 0.1%.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Glenmark Pharmaceuticals Ltd.'s market cap?
Glenmark Pharmaceuticals Ltd.'s market capitalization is INR 628.43B.
What is Glenmark Pharmaceuticals Ltd.'s P/E ratio?
Glenmark Pharmaceuticals Ltd.'s price-to-earnings (P/E) ratio is 35.0.
Does Glenmark Pharmaceuticals Ltd. pay a dividend?
Glenmark Pharmaceuticals Ltd. has a dividend yield of 0.1%.
What does Glenmark Pharmaceuticals Ltd. do?
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays.